StockData
Septerna, Inc. logo

Septerna, Inc. (SEPN) company profile

SEPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30165% above fair value
$40.02−1.65 (-3.96%)

Close on Nov 17, 2026Market cap $1.87BP/E –Yield –

About Septerna

Pharmaceutical Preparations, SIC 2834

Septerna, Inc. is a clinical-stage biotechnology company that discovers and develops oral small molecule drugs targeting G protein-coupled receptors. The company utilizes a proprietary platform to isolate, purify, and reconstitute receptor proteins outside cells to guide structure-based drug design and optimization. Its development pipeline includes experimental product candidates such as SEP-479 and SEP-631, which focus on endocrinology, immunology, inflammation, and metabolic conditions. Septerna also partners with pharmaceutical companies, including Novo Nordisk, to develop oral therapies for disorders such as obesity and type 2 diabetes. Its programs aim to serve patient populations affected by these diseases.

The company operates in the United States, maintaining leased office, research, and laboratory facilities. Its principal executive offices are located in South San Francisco, California.

Summary of the business section of Septerna's latest annual report, written by StockData.

Company profile

Company

Legal name
Septerna, Inc.
Headquarters
South San Francisco, CA
Address
250 East Grand Avenue, Suite 65 94080
Phone
(650) 338-3533
Employees
130, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
SEPN
Exchange
Nasdaq
IPO date
Oct 25, 2024
Shares outstanding
47M, Aug 5, 2026
Public float
$363.30M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1984086
CUSIP
81734D104
ISIN
US81734D1046
FIGI
BBG014WY1V28
Share class FIGI
BBG014WY1VC7
EIN
84-3891440

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jeffrey FinerChief Executive Officer, Director833,909
Elizabeth BhattPresident and COO174,209
Rajiv PatniChief Medical Officer–
Daniel D. LongSVP, Drug Discovery96,412
Samira ShaikhlyChief People Officer793
Uwe KleinSVP, Biological Sciences119,912
Jae B. KimChief Medical Officer–
Mark Andrew WilsonChief Legal Officer–
Gil M. LabrucherieChief Financial Officer40,000
Alan EzekowitzDirector35,600
Capital Healthcare Fund LP RADirector–
Peter KolchinskyDirector–
RA Capital Nexus Fund III, L.P.Director–
Rajeev M. ShahDirector725,443
Ra Capital Management, L.P.Director–
Shalini SharpDirector–
Keith Michael GottesdienerDirector–
Bernard CoulieDirector–
Jeffrey K. TongDirector–
Abraham BassanDirector–
Jake SimsonDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Jeffrey Finer, M.D., Ph.D
Chief Executive Officer
$635.00K$401.64K$1.89M$5.00K$2.93M-38%
Liz Bhatt, M.S., M.B.A
President and Chief Operating Officer
$500.00K$230.00K$855.77K$5.00K$1.59M-2%
Gil M. Labrucherie, CFA, J.D.
Chief Financial Officer (4)
$479.49K$223.10K$2.54M$2.43K$3.24M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 25, 2024
Offer price
$18.00
Securities offered
16,000,000
Gross proceeds
$288.00M
Exchange
Nasdaq
First trading day
Oct 25, 2024
First-day close
$21.40+18.9%
Lock-up ends (est.)
Apr 23, 2025

“The initial public offering price per share is $18.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 130 full-time employees, 67 of whom have M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?